Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285030 | 1.00 | MAPK8 (0.44) | MAPK8MAPK9MAPK10PIK3CDEGFR | |
| SCHEMBL22950983 | 0.92 | EGFR (0.45) | MAPK8MAPK9MAPK10EGFRACVR1 | |
| SCHEMBL22950934 | 0.91 | EGFR (0.45) | EGFRACVR1 | |
| SCHEMBL22950893 | 0.90 | EGFR (0.51) | EGFRACVR1 | |
| SCHEMBL29757784 | 0.90 | EGFR (0.51) | EGFRACVR1 | |
| SCHEMBL22950921 | 0.90 | EGFR (0.47) | MAPK10PIK3CDEGFRBTKRET | |
| SCHEMBL24780434 | 0.89 | EGFR (0.44) | EGFRIRAK4ACVR1RET | |
| SCHEMBL23759769 | 0.88 | EGFR (0.48) | EGFRACVR1RETWNT1GSK3B | |
| SCHEMBL22950966 | 0.87 | EGFR (0.43) | EGFRACVR1RET | |
| SCHEMBL28965162 | 0.85 | EGFR (0.41) | PIK3CDEGFRBTKRETTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| WO-2021160087-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021104441-A1 | POLYAROMATIC COMPOUND AS EGFR KINASE INHIBITOR | 江苏先声药业有限公司 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | MAPK8 256/4885MAPK9 68/4885MAPK10 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.